NB53 did not receive neoadjuvant therapy and the primary tumor (NB53-T1) presented an Sa+1pL genomic profile (MYCN amplification and 1p loss but no 17q gain nor 11q loss), while the liver metastatic tumor obtained 14 months after therapy (NB53-T2) exhibited a P1a pattern. This evidence concerns the gene MYCN and metastatic neoplasm.